265 results about "Lung tissue" patented technology

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The invention belongs to the technical field of medical treatment, and discloses a pulmonary nodule segmentation method and system based on a diffusion model, and the method employs a potential space fusion method based on anatomical constraint, integrates the anatomical priori knowledge of lung tissue contour and the like through a variational auto-encoder (VAE), and combines a KL divergence constraint strategy. And the sensitivity of the model to a tiny focus is effectively improved. Secondly, a multi-modal collaborative optimization FSUNet architecture is constructed, and a cross-scale feature pyramid fusion mechanism is utilized to cooperate with a channel attention gating and dynamic noise scheduling algorithm, so that the expression ability of multi-dimensional features is enhanced. And finally, designing a Dice-Focal joint loss function to suppress complex background noise interference, and meanwhile, based on a forward diffusion-based noise sample generation strategy, remarkably reducing the dependence of the model on annotated data. Experimental results on an LIDC-IDRI data set show that the diffusion segmentation method based on multi-scale feature fusion not only shows excellent performance, but also shows excellent performance on an FPS index at the same time.

The invention provides a pulmonary nodule display method and device, electronic equipment and a storage medium, and the method comprises the steps: segmenting a three-dimensional reconstruction image of the chest of a target patient to obtain a preoperative segmentation image, the three-dimensional reconstruction image being obtained based on preoperative CT data, and the preoperative segmentation image comprising the position information of a pulmonary nodule; segmenting the video image of the intraoperative lung tissue of the target patient collected by the thoracoscope in real time to obtain an intraoperative segmented image; feature matching is conducted on the preoperative segmented image and the intra-operative segmented image, the lens pose of the thoracoscope is determined, the preoperative segmented image is mapped into a two-dimensional reference image based on the lens pose, and the two-dimensional reference image comprises the position information of the pulmonary nodule; and carrying out image registration on the two-dimensional reference image and the intra-operative segmented image, and carrying out pulmonary nodule marking on the intra-operative segmented image to obtain a video image for displaying pulmonary nodules in real time. The position of the pulmonary nodule in the operation is accurately displayed in real time in a non-invasive mode, and the operation efficiency is improved.

The invention provides a compound probiotic for relieving acute lung injury and application of the compound probiotic, and particularly discloses application of the compound probiotic consisting of bifidobacterium animalis YRK-12 and lactobacillus rhamnosus LRa-Y8 in preparation of a medicine for relieving the acute lung injury. Wherein the preservation number of the bifidobacterium animalis YRK-12 is CGMCC (China General Microbiological Culture Collection Center) No.28597; the preservation number of the lactobacillus rhamnosus LRa-Y8 is CGMCC (China General Microbiological Culture Collection Center) No. 34186. Experimental verification shows that the compound probiotics can remarkably relieve acute lung injury induced by lipopolysaccharide (LPS) through a synergistic effect; specifically, the weight loss rate of mice is reduced, pathological injuries of lung tissues are improved (the structural integrity of alveolar alveoli is maintained, and inflammatory cell infiltration is reduced), the levels of proinflammatory factors (IL-1beta, TNF-alpha and IL-6) in serum and lung tissues are reduced, and the level of anti-inflammatory factors (IL-4) is increased, so that the immune balance of the lung is regulated through an intestine-lung axis; and a safe and effective novel micro-ecological regulation strategy is provided for prevention and treatment of acute lung injury.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating sepsis-related acute lung injury and application thereof. The traditional Chinese medicine composition comprises the following active pharmaceutical ingredients in parts by mass: 5-15 parts of cassia twig, 5-15 parts of rheum officinale, 10-20 parts of peach kernel, 25-35 parts of gypsum and 10-20 parts of kudzu vine root. Animal experiments show that the traditional Chinese medicine composition can effectively improve lung tissue pathological manifestations of mice with sepsis-related acute lung injury by inhibiting polarization of M1 type macrophages, promoting polarization of M2 type macrophages, improving the infiltration level of neutrophils and inhibiting release of inflammatory factors. Therefore, the traditional Chinese medicine composition disclosed by the invention has a good treatment effect on acute lung injury related to sepsis.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

The invention discloses hydrogel bio-ink, a preparation method of the hydrogel bio-ink, a 3D printing biodegradable airway stent and application of the 3D printing biodegradable airway stent. The preparation method comprises the following steps that S1, lung tissue is subjected to freeze thawing, slicing, sequential decellularization of SDS and TritonX-100, air drying, smashing and cryopreservation, and a lung extracellular matrix is obtained; s2, performing sterilization and pepsin treatment on the lung extracellular matrix prepared in S1 to obtain a pretreated lung extracellular matrix; and S3, mixing methyl propionylated gelatin and an alginate solution, pouring the mixture into solid gel, gelatinizing the solid gel, and adding the pretreated lung extracellular matrix to prepare the hydrogel bio-ink. The prepared pig lung acellular extracellular matrix does not have an obvious nuclear structure, and DNA (Deoxyribonucleic Acid) determination shows that the concentration of an acellular group is obviously reduced (P is less than 0.01); along with the increase of the dECM concentration, the porosity is reduced, and the degradation time is prolonged; the airway stent is printed in a 3D biological printing mode, no obvious cytotoxicity (P is larger than 0.05) exists in a cytotoxicity experiment, and the mechanical property part of the airway stent is similar to that of a silicone stent.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The invention relates to the technical field of medical imaging, and discloses a peripheral lung cancer pleural invasion evaluation system based on ultrasonic targeted radiography, comprising: a double-frequency ultrasonic probe configured to independently work at different frequencies to realize depth imaging and high-resolution imaging of lung tissues and suitable for different types of lung lesions; the signal processing module can receive, analyze and process echo signals transmitted by the ultrasonic probe, generate images in real time and extract feature information; and the dynamic motion compensation module is used for automatically adjusting the emission time sequence and parameter setting of the ultrasonic signal based on the real-time breathing motion state of the patient. By adopting the design of the double-frequency ultrasonic probe and the core-shell structure, high-resolution imaging and depth detection of lung tissues are realized. By dynamically adjusting the thickness of the probe shell to be matched with the frequency, the system can adapt to complex tissue environments under different physiological conditions, and image definition and stability are ensured.

The invention relates to application of roxburgh rose-derived exosomes (RrNVs) in preparation of products for preventing, improving or treating acute lung injury (ALI). Specifically, the rosa roxburghii tratt exosome (RrNVs) can effectively inhibit inflammation, improve the acute lung injury symptom, reduce the release of inflammatory cells and inflammatory mediators in the acute lung injury state, and relieve the pulmonary edema condition, the lung tissue leakage condition and the lung capillary permeability condition in the inflammatory state. Meanwhile, the RrNVs can also regulate and control the intestinal flora structure, improve the abundance of beneficial bacteria and reduce the abundance of harmful bacteria, and the discovery provides a basis for the RrNVs as potential functional food, medicine and the like of ALI.

The invention discloses a thoracic surgery pulmonary infection effusion drainage device and belongs to the technical field of medical instruments, the thoracic surgery pulmonary infection effusion drainage device comprises a drainage catheter structure, a filtering structure and a connecting assembly, the drainage catheter structure comprises an insertion tube, the two ends of the insertion tube are connected with a fixing tube and a hemispherical end respectively, and a partition plate is arranged in the insertion tube and the fixing tube; a plurality of drainage holes are formed in the end, close to the hemispherical end, of the insertion tube in the circumferential direction, and a medicine feeding hole is formed in the portion, above the drainage holes, of the insertion tube and communicated with the monitoring cavity. By means of the semispherical end and the drainage hole of the drainage catheter structure, lung tissue is prevented from being scratched when thoracic wall puncture is conducted, the lung tissue damage rate can be reduced to be smaller than or equal to 0.5%, drainage, pressure monitoring and drug administration are achieved through the double-cavity structure, one-time puncture is completed, and the pain of a patient is relieved; by arranging the partition plate, the drainage cavity and the monitoring cavity are isolated, liquid medicine is prevented from polluting an effusion sample, and the infection risk is reduced.

The invention provides application of Ulixertinib in treatment of lung tissue inflammation caused by novel coronavirus, and the Ulixertinib can effectively relieve the lung inflammatory infiltration degree after infection of the novel coronavirus, reduce the expression level of cytokines, chemotactic factors or NETs related proteins and inhibit formation of NETs. The invention provides a brand new treatment strategy for novel coronavirus infection, especially severe lung tissue inflammation caused by multiple infection of novel coronavirus.

The invention belongs to the technical field of lung tissue lesion positioning, and particularly relates to a lung tissue lesion position positioning system and method based on three-dimensional reconstruction. According to the method, overall and local two-stage registration is combined, whole-lung expansion errors are corrected, local deformation is compensated, the lesion position and image alignment is achieved, the three-dimensional lesion position is displayed through the augmented reality technology, doctors are helped to visually master spatial distribution of the focus in the body of a patient, the safety and the success rate of operation or needle biopsy are improved, and the operation efficiency is improved. Based on a breathing model and an elastic registration method, the method can adapt to lung compliance differences and breathing movement conditions of different patients, is particularly suitable for severe or old patients difficult to keep stable breathing, reduces the risk of blind penetration or excessive resection through accurate positioning, and reduces tissue damage and the occurrence rate of postoperative complications.

The invention relates to application of visceral odorobacter and outer membrane vesicles thereof in preparation of drugs for treating acute lung injury, and relates to the technical field of drugs. The modeling medicine lipopolysaccharide is applied to a mouse individual in a nasal dripping mode, the administration mode is that each mouse is administered once a day, and intragastric administration is carried out once a day after modeling is carried out for two days and lasts for 7 days. Experiments prove that visceral odorobacter and outer membrane vesicles of the visceral odorobacter reduce the number of M1 type alveolar macrophages by down-regulating proinflammatory factors IL-6, TNF-alpha and IL-1beta in lung tissues and inhibiting three proinflammatory factors IL-6, TNF-alpha and IL-1beta in serum, so that the effect of remarkably reversing acute lung injury is achieved. The visceral odor bacilli and the outer membrane vesicles thereof are used for preventing and treating the acute lung injury, and a new method and means are provided for clinically treating the acute lung injury.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.

The invention discloses a high-frequency full-chest oscillation sputum excretion method and system based on clinical data self-adaptive regulation and control, and the method comprises the steps: building an individualized propagation model of thorax and lung tissues through collecting individualized clinical data of a patient and chest multipoint acoustic and mechanical short-range response; the current body position of a patient is input into the model, a chest drainage path is obtained, oscillation control parameters are generated under the constraint of the path, and the oscillation control parameters are used for driving equipment to synthesize pressure traveling waves which are directionally propagated in multiple areas of the chest wall. In the execution process, safety gating control is conducted in combination with electrocardio and breathing phases, meanwhile, aerosol echoes and high-frequency impedance disturbance are collected to serve as feedback signals, and feedback data are formed after the feedback signals are aligned with an execution time sequence and used for dynamically updating the individualized propagation model and oscillation control parameters. According to the invention, accurate regulation and control can be carried out according to individual differences and real-time physiological statuses of different patients, the sputum drainage effect is effectively enhanced, the safety and comfort of treatment are improved, and the clinical application value is high.

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The invention belongs to the technical field of medicine, particularly relates to application of isodan-leaf emodin in preparation of a CXCL10 inhibitor, and particularly relates to application of the isodan-leaf emodin in treatment of sepsis lung injury, and by establishing a sepsis lung injury model induced by cecum ligation puncture (CLP), the application of the isodan-leaf emodin in preparation of the CXCL10 inhibitor is established. It is proved that the polyphenol monomer drug isodan leaf emodin can significantly improve lung tissue pathological damage, reduce the level of inflammatory factors in lung tissue, inhibit oxidative stress reaction and improve the survival rate of a CLP model. Experiments show that the isodan leaf emodin with the dosage of 25 mg / kg can relieve pulmonary edema and inflammatory response by inhibiting secretion of CXCL10, and a new scheme is provided for treatment of sepsis-related lung injury.

The invention relates to the technical field of radiotherapy, and discloses a multi-modal image fusion guided chest tumor adaptive radiotherapy system. The system comprises an asynchronous bimodal sensing module, a spectrum preprocessing module, a parameter inversion module, a boundary construction module and a biomechanical calculation module. According to the method, the feedback voxel-level velocity field is utilized to execute Lagrange reverse warping on the high-energy projection with physical time delay, and motion artifacts are eliminated; and dynamically updating the Young modulus of the lung tissue mechanical model based on the inverted real-time electron density, and solving a full-field three-dimensional displacement field in combination with double boundary conditions of body surface flexibility and internal skeleton rigidity so as to reconstruct a tumor target region and generate a beam control instruction. According to the method, through closed-loop interaction of image physics and biomechanics, the problems of dual-energy imaging motion artifact interference and insufficient lung tissue fixed parameter modeling precision are solved, and accurate self-adaptive tracking of a tumor target region is realized.

The application discloses an FPR1 polypeptide blocker against lung inflammation and application thereof. The application provides a polypeptide shown in Sequence NO. 1, which can significantly improve lung tissue structure damage of a lung inflammation model mouse, reduce a proinflammatory factor level, reduce neutrophil infiltration, and show obvious anti-lung inflammation efficacy. Therefore, the polypeptide shown in Sequence NO. 1 has a prospect of development into an anti-lung inflammation drug.

The invention relates to the technical field of hydrops quantitative evaluation, and discloses an ultrasound-based pleural hydrops quantitative evaluation system, which comprises an image acquisition module, a boundary division module, a trajectory analysis module, a feature judgment module, a mode classification module and a quantitative evaluation determination module, the positioning module is used for positioning an area which deforms along with breathing movement in the ultrasonic image sequence, and dividing a suspected effusion cavity boundary based on the consistency of a deformation mode; the trajectory analysis module is used for analyzing moving trajectories of the suspected effusion cavity boundary at different breathing phases and extracting regularity features and amplitude change features of the moving trajectories; the feature judgment module is used for judging the mechanical coupling state of the suspected effusion cavity and the surrounding lung tissue according to the combination of the regularity feature and the amplitude change feature; according to the method, the comprehensiveness and accuracy of quantitative evaluation of the pleural effusion are remarkably improved, and a more valuable decision basis is provided for clinical diagnosis and treatment.

The present invention relates to an ambroxol-ibuprofen cocrystal dry powder inhaler, a preparation method and application thereof, and belongs to the professional field of pharmaceutical preparations. The dry powder inhaler is mainly composed of ambroxol, ibuprofen and lactose, the molar ratio of ambroxol to ibuprofen is 1:1, and the mass ratio of lactose to ambroxol-ibuprofen cocrystal is 5-35%. The results of the rat lung tissue distribution experiment showed that the administration method of dry powder inhalation can significantly enhance the drug delivery efficiency in the lungs and greatly prolong the drug retention time in the lungs compared with the traditional intravenous administration. Pharmacodynamic experiments further revealed that the ambroxol-ibuprofen cocrystal dry powder inhaler can effectively inhibit the active expression of inflammatory factors in model animals, and reduce the accumulation of hydroxyproline (HYP) in lung tissue and serum, improve anti-fibrosis and anti-inflammatory capabilities, improve oxidative stress capabilities, thereby helping to delay the pathological process of pulmonary fibrosis, showing great development potential as an anti-pulmonary fibrosis drug.